32nd ESHO meeting focuses on hyperthermia in the multimodal treatment of cancer and abdominal tumors
The focus of this year’s meeting will be on the “multimodal treatment of abdominal tumors involving thermal therapy - potential and caveats.“ This topic has attracted a number of world class speakers who will join interdisciplinary congress sessions with clinicians from various areas of oncological expertise.
The 2018 ESHO program also includes a Patient Information Day, in German, including a get-together. Sponsored by Dr. Sennewald Medizintechnik GmbH, this event takes place on May 19 from 10:30 to 12:30, and will cover the following topics:
Hyperthermia’s role in enhancing the efficacy of chemotherapy (Lars Lindner, Munich/DE)
Hyperthermia’s role in enhancing the efficacy of radiotherapy (Stephan Bodis, Aarau/CH)
Hyperthermia in the treatment of tumors in children and young adults (Georg Seifert, Berlin/DE)
Hyperthermia in practice: Approaches to capacitive and full-body hyperthermia (Holger Wehner, Wilhelmshaven/DE).
The Patient Information Day and the get-together will be held at Campus Charité Universitätsmedizin Berlin, Hörsaal Innere Medizin, Virchowweg 9.
Dr. Sennewald Medizintechnik GmbH would also like to point out that the company will be holding a lunch symposium on Pyrexar Innovations 2018. For further details please follow the link: https://gallery.mailchimp.com/872d09033f420335504ad1a7e/files/4a930aa5-23eb-4796-8e51-1f3d0fd8e983/AZ_ESHO_B_R%C3%BCck148x210_4.pdf
Interview with Dr. Pirus Ghadjar on the EORTC 62961-ESHO 95 trial recently published in JAMA: https://gallery.mailchimp.com/872d09033f420335504ad1a7e/files/de25f088-41cc-4dec-a345-14b234c425c5/Interview_Dr._Ghagjar_V2.02.pdf
YouTube video on image-guided hyperthermia: https://youtu.be/0ETZMAfAaDw
Dr. Sennewald Medizintechnik was founded with the aim of discovering innovative and beneficial cancer therapies and has since amassed over 30 years of experience in regional and local hyperthermia. To achieve this goal, the company entered into a long-term partnership with the pioneers and world leaders, Pyrexar Medical, to further develop the manufacture of hyperthermia systems. The companies’ links to the scientific community have led to the acceptance of hyperthermia, the development of dedicated software, reimbursement of hyperthermia and its use in the treatment of children. Strategic partnerships with medical centers have resulted in phase III clinical studies demonstrating that Pyrexar systems offer a significant increase in cancer response rates and are the only ones to have received FDA approval.
Dr. Sennewald Medizintechnik GmbH can draw on its many years of experience for the company’s in-depth knowledge of customers’ clinical requirements and of the precise technical specifications for all the hyperthermia systems on offer. In addition, teams of engineers, technicians and software developers remain as close to customers as possible, offering support in the planning, installation and set-up of the systems, as well as after-sales service.
Dr. Sennewald Medizintechnik GmbH
81829 München / Germany
Monica Sennewald, Marketing Director
T: +49 89 542143-25
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 32nd ESHO meeting focuses on hyperthermia in the multimodal treatment of cancer and abdominal tumors here
News-ID: 1043583 • Views: 563
More Releases from Dr. Sennewald Medizintechnik GmbH
Hyperthermia doubles cancer response rate
Munich, March 9, 2017: Clinical data has already demonstrated that adding superficial hyperthermia to radiation in the treatment of recurrent breast cancer and malignant melanoma can double the complete response rate (1). Now a new report published in the "International Journal of Hyperthermia" proves that radiated hyperthermia is the superior method for the treatment of these superficial cancerous tumors. Hyperthermia, i.e. the heating of tumors to temperatures of 41-45 °C
More Releases for ESHO
Full speed ahead – New Celsius42
Eschweiler 01.05.2018 - The relaunch of Celsius42 GmbH is just a few days away. After 4 months and many hours of work by our creative team, we look forward to publishing our new company website in the near future. “This innovation represents a true milestone for the development of Celsius42,” says Christian Hartmann, the company’s new CEO. “In addition to the remake of our corporate identity, there are many ongoing